Coya Therapeutics Announces $46.8M Cash Balance, Extends Runway to H2 2027, and Targets Q1 2027 for Phase 2 Data
Summary
Coya Therapeutics reported an unaudited cash balance of $46.8 million as of December 31, 2025, projecting a cash runway into the second half of 2027. The company also expects topline data from its ALSTARS Phase 2 trial in the first quarter of 2027.
Key Events
-
Strong Cash Position Reported
Coya Therapeutics announced an unaudited cash balance of $46.8 million as of December 31, 2025.
-
Extended Cash Runway
The company projects this cash balance will fund its operations into the second half of 2027, significantly extending its financial stability.
-
Key Clinical Data Expected
Topline data from the ALSTARS Phase 2 trial is anticipated in the first quarter of 2027, marking a significant upcoming milestone.
Analysis
Coya Therapeutics' announcement of a substantial cash balance and an extended operational runway into the second half of 2027 significantly de-risks the company's financial position. For a life sciences company, this reduces immediate concerns about capital raises and potential dilution, providing stability to advance its clinical programs. The clear timeline for the ALSTARS Phase 2 trial data readout in Q1 2027 also provides investors with a critical catalyst to monitor, as successful clinical data is paramount for biotech valuation.
At the time of this filing, COYA was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $89.6M. The 52-week trading range was $3.94 to $8.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.